Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBIT Margin (2020 - 2025)

Apellis Pharmaceuticals has reported EBIT Margin over the past 6 years, most recently at 25.58% for Q4 2025.

  • Quarterly results put EBIT Margin at 25.58% for Q4 2025, down 7146.0% from a year ago — trailing twelve months through Dec 2025 was 5.52% (up 1081.0% YoY), and the annual figure for FY2025 was 5.52%, up 1081.0%.
  • EBIT Margin for Q4 2025 was 25.58% at Apellis Pharmaceuticals, down from 48.67% in the prior quarter.
  • Over the last five years, EBIT Margin for APLS hit a ceiling of 481.36% in Q4 2021 and a floor of 31185.71% in Q2 2021.
  • Median EBIT Margin over the past 5 years was 49.96% (2025), compared with a mean of 1931.08%.
  • Peak annual rise in EBIT Margin hit 3027514bps in 2022, while the deepest fall reached -120524bps in 2022.
  • Apellis Pharmaceuticals' EBIT Margin stood at 481.36% in 2021, then crashed by -250bps to 723.88% in 2022, then surged by 130bps to 220.01% in 2023, then plummeted by -79bps to 45.88% in 2024, then plummeted by -156bps to 25.58% in 2025.
  • The last three reported values for EBIT Margin were 25.58% (Q4 2025), 48.67% (Q3 2025), and 18.65% (Q2 2025) per Business Quant data.